Phaseline

Companies › Luminary Therapeutics

Luminary Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LMY-920
BAFF CAR-T cells targeting BAFF ligand
TNFSF13BPhase 1Systemic Lupus Erythematosus–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06340750LMY-920Phase 1Systemic Lupus ErythematosusImmunologyApr 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

TNFSF13B (1)

Companies with the same targets

GSK Vera Therapeutics Zura Bio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.